CIK 0001650664 · Non-accelerated filer<br>Smaller reporting company
Editas Medicine, Inc.
Sign in to watch- Ticker
- EDIT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464097528
- Phone
- 617-401-9000
- Business address
- 11 HURLEY ST., CAMBRIDGE, MA, 02141
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $19,092
- in 3 filings, $19K under 10b5-1 plans
Net −$19,092. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-02 | Mei Baisong SVP, CHIEF MEDICAL OFFICER | Grant or award 10b5-1 | +19,458 | 142,413 | ||
| 2024-03-02 | Mei Baisong SVP, CHIEF MEDICAL OFFICER | Grant or award 10b5-1 | +19,457 | 161,870 | ||
| 2024-03-02 | Mei Baisong SVP, CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) 10b5-1 | +152,800 | 152,800 | ||
| 2023-12-05 | Eaton Bruce EVP, CBO AND CTO | Sale 10b5-1 | −103 | $10.90 | $1K | 74,791 |
| 2023-11-14 | Eaton Bruce EVP, CBO AND CTO | Sale 10b5-1 | −695 | $8.21 | $6K | 74,894 |
| 2023-11-07 | Eaton Bruce EVP, CBO AND CTO | Sale 10b5-1 | −139 | $8.40 | $1K | 75,589 |
| 2023-09-06 | Eaton Bruce EVP, CBO AND CTO | Sale 10b5-1 | −103 | $8.82 | $908 | 75,728 |
| 2023-08-11 | Eaton Bruce EVP, CBO AND CTO | Sale 10b5-1 | −702 | $8.59 | $6K | 75,831 |
| 2023-08-08 | Eaton Bruce EVP, CBO AND CTO | Sale 10b5-1 | −141 | $8.39 | $1K | 76,533 |
| 2023-07-24 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Grant or award | +45,167 | 45,167 | ||
| 2023-07-24 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (right to buy) | +135,500 | 135,500 | ||
| 2023-07-19 | Mei Baisong SVP, CHIEF MEDICAL OFFICER | Sale 10b5-1 | −4,317 | $8.80 | $38K | 72,055 |
| 2023-06-05 | O'Neill Gilmore Neil CEO | Sale 10b5-1 | −6,486 | $9.50 | $62K | 130,169 |
| 2023-06-05 | Eaton Bruce EVP, CBO AND CTO | Sale 10b5-1 | −105 | $9.50 | $998 | 76,674 |
| 2023-06-01 | Reeve Emma Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2023-06-01 | Connaughton Bernadette Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2023-06-01 | Vaishnaw Akshay Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2023-06-01 | Scadden David Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2023-06-01 | Hopfield Jessica Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2023-06-01 | Hirsch Andrew Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 |
Page 5 of 15 · 283 trades